|
[1]
|
Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J]. N Engl J Med, 2010. 363(5): 411-422. doi: 10.1056/NEJMoa1001294
|
|
[2]
|
Zarei S, Schwenter F, Luy P, et al. Role of GM-CSF signaling in cell-based tumor immunization[J]. Blood, 2009, 113(26): 6658-6668. doi: 10.1182/blood-2008-06-161075
|
|
[3]
|
HodiFS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients[J]. Proc Natl Acad Sci U S A, 2008, 105(8): 3005-3010. doi: 10.1073/pnas.0712237105
|
|
[4]
|
Gajewski TF, Louahed J, Brichard VG. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy[J]. Cancer J, 2010, 16(4): 399-403. doi: 10.1097/PPO.0b013e3181eacbd8
|
|
[5]
|
Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993[J]. J Clin Oncol, 1999, 17(7): 2105-2116. doi: 10.1200/JCO.1999.17.7.2105
|
|
[6]
|
Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma[J]. N Engl J Med, 2011, 364(22): 2119-2127. doi: 10.1056/NEJMoa1012863
|
|
[7]
|
Zhang L, Kerkar SP, Yu Z, et al. Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment[J]. Mol Ther, 2011, 19(4): 751-759. doi: 10.1038/mt.2010.313
|
|
[8]
|
Petrella TM, Belnager K. Interleukin-21 (IL-21) activity in patients with metastatic melanoma (MM)[J]. J Clin Oncol, 2010, 28: 15s(abstract 8507).
|
|
[9]
|
Lawson DH, Tarhini AA. E4697: phase Ⅲ cooperative group study of yeast-derived granulocyte macrophage colony-stimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage Ⅲ-Ⅳ melanoma[J]. J Clin Oncol, 2010, 28S (abstract 8504).
|
|
[10]
|
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723. doi: 10.1056/NEJMoa1003466
|
|
[11]
|
Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. N Engl J Med, 2011, 364(26): 2517-2526. doi: 10.1056/NEJMoa1104621
|
|
[12]
|
Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation[J]. N Engl J Med, 2011, 364(26): 2507-2516. doi: 10.1056/NEJMoa1103782
|
|
[13]
|
Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates [J]. J Clin Oncol, 2010, 28(19): 3167-3175. doi: 10.1200/JCO.2009.26.7609
|
|
[14]
|
Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors[J]. Proc Natl Acad Sci U S A, 2010, 107(9): 4275-4280. doi: 10.1073/pnas.0915174107
|
|
[15]
|
Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody[J]. J Clin Oncol, 2007, 25(7): 876-883. doi: 10.1200/JCO.2006.08.3311
|
|
[16]
|
Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report[J]. N Engl J Med, 1988, 319(25): 1676-1680. doi: 10.1056/NEJM198812223192527
|
|
[17]
|
Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy[J]. Nat Rev Cancer, 2008. 8(4): 299-308. doi: 10.1038/nrc2355
|
|
[18]
|
Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know[J]. Nat Rev Clin Oncol, 2011, 8(10): 577-585. doi: 10.1038/nrclinonc.2011.116
|
|
[19]
|
Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes[J]. Science, 2006, 314(5796): 126-129. doi: 10.1126/science.1129003
|
|
[20]
|
Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1[J]. J Clin Oncol, 2011, 29(7): 917-924. doi: 10.1200/JCO.2010.32.2537
|
|
[21]
|
Cartellieri M, Bachmann M, Feldmann A, et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer[J]. J Biomed Biotechnol, 2010, 2010: 956304.
|
|
[22]
|
Park TS, Rosenberg SA, Morgan RA. Rosenberg, and R.A. Morgan, Treating cancer with genetically engineered T cells[J]. Trends Biotechnol, 2011, 29(11): 550-557. doi: 10.1016/j.tibtech.2011.04.009
|
点击查看大图
下载:
